Alira Health and HTAi Collaborate to Develop a Multi-Stakeholder Value Assessment Framework for Robotic-Assisted Surgery & Digital Health

Alira Health, a global healthcare consulting and technology firm with expertise in Health Technology Assessment (HTA) methodology, will coordinate the discussion and consensus of evidence-based guidance on HTA for Robotic-Assisted Surgery (RAS) and Digital Health Technologies.

This multi-stakeholder Value Assessment Framework will provide guidance on how to overcome challenges in determining the cost-effectiveness of robotic-assisted surgery from the perspectives of patients, physicians, and payers.

The framework, designed in collaboration with the HTAi Medical Device Interest Group, is technology and company agnostic. Key areas of guidance will include:

  • best practices in assessing the value of robotic-assisted surgery at both the national and hospital level;
  • how to support the implementation of RAS and Digital Health programs globally;
  • how to ensure the clinician and patient perspectives are included in the quantification of value.

The following areas of consensus will be sought from a panel of leading robotic-assisted surgeons, leading health economists, and policymakers:

  • Clinical Challenges
    • Evidence type and quality (RCT vs RWE)
    • Physician and patient-reported outcomes
    • Physician learning curve
  • Economic Challenges
    • Appropriate Time Horizon for evaluation
    • Challenges of a high upfront capital investment
    • Organizational impact on surgical procedures
  • Digital Challenges
    • Evaluation of an increasingly digitally-enabled RAS ecosystem
    • Overcoming the rapid evolution of digital solutions
Published on:
March 22, 2022
"The guidance will be aimed at HTA agencies globally and will allow them to better assess the value of robotic surgical and digital health systems. We are pleased to be overseeing the operation of such a crucial project and contributing to the development of the consensus document and scientific publication with the recommendations for HTA agencies."
Richard Charter Vice President MedTech Market Access - Europe & Asia Pacific at Alira Health

About Alira Health

Alira Health is an international patient-centric and technology-enabled advisory firm whose mission is to humanize healthcare. We work with healthcare and life sciences organizations looking for support across their entire solutions lifecycle. From development to medical care, we complement our clients’ expertise with a full spectrum of services including research and clinical development solutions, technology-powered consulting, and real-world evidence.

Our integrated and multidisciplinary team of over 500 scientists, strategists, economists, clinicians, and biostatisticians collaborate across our North American, European, and Asian offices and advise 80% of the top 50% of MedTech companies and 75% of the top 50% of Pharma companies.

About HTAi

Health Technology Assessment international (HTAi) is the global, non-profit, scientific, and professional society for all those who produce, use or encounter health technology assessment (HTA). The society represents 82 organizations and over 2,500 individual members from 65 countries around the world.

Related news

Events January 27, 2023
Alira Health and Biocat Startup Support Program Presentation
Biocat and Alira Health partnered to foster Market Access for startups. Alira Health, a global healthcare advisory and technology company, and Biocat, a strategic stakeholder building(...)
Market Access Startups
Publications January 20, 2023
Insights on Market Access
To get her perspective on market access and what to expect in 2023, we spoke with Nerea Blanqué, Senior Vice President of Market Access and Pricing at Alira Health.
Market Access Medical Devices Pharma
Publications December 21, 2022
2022 Recap: Your Favorite Alira Health Publications
In 2022, the Alira Health team of scientists, strategists, economists, clinicians, and biostatisticians shared actionable insights, industry thought leadership, and leading-edge guidance(...)
Clinical Digital Health Market Access MedTech Pharma Regulatory
News November 15, 2022
Alira Health Partners with Policy Matters to Foster Market Access in the UK
Alira Health, a global advisory and clinical research firm whose mission is to humanize healthcare and life sciences, announces its partnership with leading UK market access specialist(...)
Digital Health Healthcare Consulting Market Access
News November 10, 2022
Alira Health and GDMH together to boost Life Sciences innovation
The companies join forces for collaborative research and co-development of projects in the fields of Digital Health, Real-World Evidence and Market Access.
Clinical Trials Digital Health DTx Market Access Real-World Evidence RWE
Events October 7, 2022
Debate Sobre los IPT en Oncología
We are pleased to announce our next event, “Debate Sobre los IPT en Oncología,” focusing on price and reimbursement (P&R) of vital oncology and oncohematology therapies.
Market Access Product Development Regulatory
Publications October 5, 2022
Relative Weight of the Variables Evaluated Through the Therapeutic Positioning Reports in the Pricing and Reimbursement of Oncological and Oncohematology Medicines in Spain
Discover how companies’ target prices are impacted by the different variables leveraged during the P&R process for oncology and oncohematology’s first indication.
Market Access Oncology Spain
Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.